Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Jul 13 2017

Hadassah Gives Gift of Hearing to Deaf Boy from Gaza

Mohammed, a youngster from Gaza, was born without the ability to hear. Thanks to Hadassah Hospital Ein Kerem’s sophisticated technology and treatment, Mohammed is no longer deaf.

READ MORE ›
alt_text

Wednesday, Jul 12 2017

The Woman Behind the Trailblazing Treatment

Hadassah’s Prof. Michal Lotem, a trailblazer in melanoma research and healing, is treating her patients with a personalized protocol that only a handful of oncology centers around the globe are able to offer.

READ MORE ›
alt_text

Wednesday, Jul 12 2017

Medical Clown Nehama’s Blog, Chapter Three

In this blog, I bring you a lyrical story by Medical Clown Shiri Breuer, entitled “Miracles Do Happen.”

READ MORE ›
alt_text

Monday, Jul 10 2017

HMO Docs Perform Rare In-Utero Heart Surgery

In a risky and delicate in-utero procedure performed for the first time in Israel, an interdisciplinary team of Hadassah Medical Organization doctors saved the life of a 28-week-old fetus with a severe heart defect.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More